JUL 0 6 ma

AT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL ASS MAIL IN AN ENVELOPE ADDRESSED TO: MAIL STOP AMTECRICENT COMMISSIONER P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE INDICATED BELC

PATENT MAIL STOP AMENDMENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:

Patent Application of Thomas Maciag, et al.

: Group Art Unit: 1635

Appln. No.:

10/022,554

Examiner: Jon E. Angell

Filed:

December 17, 2001

Attorney Docket

No. 54474-5005

For:

COMPOSITIONS, METHODS AND KITS

(53689-5023)

RELATING TO THROMBIN

DEGRADATION RESISTANT FIBROBLAST

GROWTH FACTOR-1

RESPONSE TO RESTRICTION REQUIREMENT

This Response is responsive to the Restriction Requirement mailed June 1, 2004 (Paper No. 8), in the above-captioned application. This Response is being timely filed.

Responsive to the Restriction Requirement, Applicants hereby elect to prosecute the claims of Group I, Claims 1-17, and 27, drawn to an isolated nucleic acid encoding a fibroblast growth factor-1 resistant to thrombin degradation, wherein the nucleic acid comprises the sequence of SEQ ID NO:3, or the nucleic acid comprises the sequence of SEQ ID NO:1 with mutation at position of 443 to 445, a vector, and a recombinant cell, and a composition comprising an isolated nucleic acid comprising the sequence of SEQ ID NO:3, or a fragment, or derivative thereof.

This election is made without traverse and without prejudice to the inclusion of the subject matter of the non-elected claims in any later-filed application.

Favorable examination of claims 1-17, and 27 is respectfully requested.

Respectfully submitted,

THOMAS MACIAG ET AL.

June 28, 2004 Date

By: James along RAQUEL M. ALVAREZ, Ph.D., J.D.

Registration No. 45,807

MORGAN, LEWIS & BOCKIUS, L.L.P.

1701 Market Street

Philadelphia, PA 19103-2921 Telephone: (215) 963-5000 Direct Dial: (215) 963-5403

Facsimile: (215) 963-5001

E-Mail: ralvarez@morganlewis.com

Attorney for Applicants

RMA/QDN